Subscribe to Newsletter

Rob Coker Deputy Editor of The Medicine Maker

Following a Bachelor’s degree in English Literature and a Master’s in Creative Writing, I entered the world of publishing as a proofreader, working my way up to editor. The career so far has taken me to some amazing places, and I’m excited to see where I can go with Texere and The Medicine Maker.

Content by Rob Coker:

 Business & Regulation Standards & Regulation

Disrupted Development

| Rob Coker | 3 min read

The political situation in the US and its impact on science and medicine is changing rapidly. Here’s a quick look at the latest developments.
Business & Regulation Bioprocessing - Upstream & Downstream

ADC Innovation: The Road Ahead

| Rob Coker | 5 min read

ADCs have shown their promise, but the next step is realizing their potential.
Discovery & Development Drug Discovery

Hidden Pathways on the Surface of Cells

| Rob Coker | 1 min read

Advances in computer simulations allow researchers to look at G protein-coupled receptors in more detail than ever before.

Business & Regulation Standards & Regulation

FDA to Phase Out Animal Testing

| Rob Coker | 2 min read

FDA to phase out mandatory animal testing with human-relevant methods for drug development
Manufacture Advanced Medicine

Coming Soon: the Power List

| Rob Coker | 2 min read

The 2025 Power List will be available soon!
Discovery & Development Drug Discovery

Antibiotics: Going With the Flow

| Rob Coker | 2 min read

How fluid flow through the body can affect the ways in which antibiotics work.
Business & Regulation Standards & Regulation

Vaccines and Autism: Perpetuating a Populist Agenda

| Rob Coker | 3 min read

Rumours claim that a well-known vaccine skeptic has been appointed to lead study on links between vaccines and autism.
Business & Regulation Business Practice

Calling Out Misleading Information

| Rob Coker | 2 min read

FDA letter sent to Edenbridge Pharmaceuticals demonstrates the challenges of getting pharma advertising right.
Business & Regulation Standards & Regulation

GSK’s Flovent Strategy Under Federal Scrutiny?

| Rob Coker | 2 min read

US Senator Elizabeth Warren calls for a federal investigation into GSK and its discontinuation of Flovent HFA
Discovery & Development Drug Discovery

Hail to the Hardy Tardigrade

| Rob Coker | 2 min read

Why scientists are looking to the microscopic marvel of the tardigrade for new approaches to cancer treatment.
Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register

February Issue of The Medicine Maker